News

New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with…

10 months ago

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to…

10 months ago

SS Innovations International Presents at MoneyShow Virtual Expo

“The Progression of Surgical Robotics: Introducing the SSi Mantra System” Video Presentation Now Available for Viewing FORT LAUDERDALE, FL, June…

10 months ago

Inspire Medical Systems, Inc. Announces FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling

MINNEAPOLIS, June 09, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…

10 months ago

Colorado Governor Jared Polis Named Opening Speaker for Psychedelic Science 2023

Governor Polis to kick off the world's largest gathering of the psychedelic ecosystem in DenverDENVER, June 09, 2023 (GLOBE NEWSWIRE)…

10 months ago

Crinetics to Highlight Broad Pipeline at ENDO 2023

Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE)…

10 months ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform

Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust…

10 months ago

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

CLEVELAND, June 09, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received feedback from the…

10 months ago

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICMLLAUSANNE,…

10 months ago